Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
ASKA Obtains Marketing Authorization of Emergency Contraceptive Pill NORLEVO as Switch to OTC Use and Daiichi Sankyo Healthcare Handles Distributio
【Delayed】(Progress of Disclosed Matters) Notice Concerning Continuation of the Response Policy to Large-scale Purchase etc. of Company Share
ASKA Pharmaceutical Announces 20th Anniversary Initiatives
Notice Regarding Termination of Procedures Based on the Response Policy to Large-scale Purchase of Company Share Certificates etc., Following the With
Toray and ASKA Terminate Business Collaboration Agreement for Adhesion Barrier Agent TRM-270
Personnel Change of ASKA Pharmaceutical
Notice Concerning Repeated Request Made to Company Shareholders Dalton etc. for Responses to Information List Pertaining to Large-scale Purchase etc.
Notice Concerning Request Made to Company Shareholders Daltone etc. for Responses to Information List Pertaining to the Large-scale Purchase etc.
Notice Concerning Delivery of Information List Pertaining to the Large-scale Purchase etc. of Company Share Certificates etc
Personnel Changes of ASKA Pharma Medical
Personnel Changes of Corporate Officers
Personnel Changes of ASKA Pharmaceutical Holdings
Personnel Changes of ASKA Pharmaceutical
MICIN and ASKA Enter into Agreement on Joint Development and Marketing of Irritable Bowel Syndrome Treatment App
Notice Concerning Receipt of Statement of Intent for the Large-scale Purchase Actions etc. Pertaining to the Large-scale Purchase etc.
ASKA Obtains Manufacturing and Marketing Approval for LEUPRORELIN ACETATE SR FOR INJECTION KIT
Notice Concerning Completion of Payment for Disposal of Treasury Shares as Remuneration for Restricted Shares
Supplementary Documents for 1Q FY2025
ASKA Pharma, Apr-Jun (1Q) Ordinary Profit Decreases by 11%
Consolidated Financial Results for the First Quarter of FY2025